Crohn DiseasePhase 3NCT02974322
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3 study testing GED-0301 in people with Crohn Disease, run by Celgene at 311 sites in 30 countries.
Trial summary
The purpose of study is to test the effect of an experimental medication GED-0301(mongersen) and evaluate its safety in patients (≥ 12 years of age) with active Crohn's disease. The study will test GED-0301 compare to placebo for 12 weeks. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Crohn Disease
- What is being tested?
- GED-0301
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 311 sitesin 30 countries
- Study dates
- 1 Dec 2017to 24 Dec 2018
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Subjects must satisfy the following criteria to be enrolled in the study:
- Male or female ≥ 12 years
- Subject is able to swallow the IP tablets
- Active Crohn's disease (CD) disease as determined by the Crohn's Disease Activity Index (CDAI) score and the Simple Endoscopic Score for Crohn's Disease (SES-CD)
- Must meet a determined average minimum number of daily stools or rating of abdominal pain over a 7day period
- Subject must have failed or experienced intolerance to at least one of the following: budesonide; systemic corticosteroids; immunosuppressants (eg, azathiopurine, 6-mercaptopurine, or methotrexate); or biologics for the treatment of CD (ie, infliximab, adalimumab, certolizumab, or vedolizumab).
Who cannot join
- The presence of any of the following will exclude a subject from enrollment: Diagnosis of ulcerative colitis (UC), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis, or colitis due to immunodeficiency
- Local manifestations of Crohn's Disease (CD) such as abscesses, short bowel syndrome; or other disease complications for which surgery might be indicated or could confound the evaluation of efficacy
- Subject has strictures with prestenotic dilatation, requiring procedural intervention, or with obstructive symptoms. In addition, subjects with colonic strictures that are not passable with an age-appropriate colonoscope, or strictures in the ileum or ileocecal valve that are fibrotic in nature, will be excluded
- Intestinal resection within 6 months or any intra-abdominal surgery within 3 months prior to the Screening Visit
- Ileostomy or a colostomy
- Subject has a history of any clinically significant medical condition that, in the investigator's opinion, would prevent the subject from participating in the study
- Adolescents with delayed growth or pubertal development who are on corticosteroids at baseline and who should not continue treatment with the same dose of corticosteroids until the Week 12 visit.
Trial locations and contacts
311 sites in 30 countries.
311 sites in 30 countries
United States136 sites
Ohio Clinical Research Partners LLC
Akron, Ohio, 44333
University of Michigan Health System
Ann Arbor, Michigan, 48105
Texas Clinical Research Institute LLC
Arlington, Texas, 76012
Asheville Gastroenterology Associates, P.A.
Asheville, North Carolina, 28801
Georgia Regents University
Augusta, Georgia, 30912
University Of Colorado
Aurora, Colorado, 80045
University of Maryland Medical Group
Baltimore, Maryland, 21201
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21218
Gastroenterology Associates, LLC
Baton Rouge, Louisiana, 70809
Clinical Inquest Center Ltd
Beavercreek, Ohio, 45431
Ehrhardt Clinical Research, LLC
Belton, Missouri, 64012
Boston Medical Center
Boston, Massachusetts, 02118
Graves Gilbert Clinic
Bowling Green, Kentucky, 42101
Connecticut Gastroenterology Institute
Bristol, Connecticut, 06010
Lahey Clinic Inc. - PARENT ACCOUNT
Burlington, Massachusetts, 01805
Medex Research Institute
Caro, Michigan, 48723
Dr. Deepak Sarwal, MD
Centerville, Ohio, 45429
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514
Carolinas Healthcare System
Charleston, South Carolina, 28203
Carolina Center for Liver Disease
Charlotte, North Carolina, 28203
Gaffney Health Services
Charlotte, North Carolina, 28205
University of Virginia
Charlottesville, Virginia, 22908
Charlottesville Medical Research Center
Charlottesville, Virginia, 22911
ClinSearch LLC
Chattanooga, Tennessee, 37421
Gastroenterology Associates of Tidewater
Chesapeake, Virginia, 23320
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, 48047
Northwestern University-Feinberg School of Medicine
Chicago, Illinois, 60611
Rush University Medical Center
Chicago, Illinois, 60612
UC Health Clinical Trials Office
Cincinnati, Ohio, 45206
Consultants for Clinical Research Inc.
Cincinnati, Ohio, 45219
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Iowa Digestive Disease Center
Clive, Iowa, 50325
Columbus Regional Research Institute
Columbus, Georgia, 31904
AGA Clinical Research Associates LLC
Egg Harbor, New Jersey, 08234
Northshore University Healthsystem Research Institute
Evanston, Illinois, 60201
Valley View Internal Medicine
Garden Grove, California, 92843
Gastro One
Germantown, Tennessee, 38138
North Shore-LIJ Health System-Division of Rheumatology
Great Neck, New York, 11021
NYU Langone Long Island Clinical Research Associates
Great Neck, New York, 11021
PhysiqueMed Clinical Trials
Greensboro, North Carolina, 27455
Medical Research Center of Connecticut LLC
Hamden, Connecticut, 06518
Connecticut GI PC Research Division
Hartford, Connecticut, 06106
Main Line Gastroenterology
Havertown, Pennsylvania, 19083-2742
Gulf Coast Research Group LLC
Houston, Texas, 77004
Methodist Hospital
Houston, Texas, 77030
University of Texas Health Science Center at Houston
Houston, Texas, 77030
Houston Endoscopy and Research Center
Houston, Texas, 77079
Indiana University School of Medicine
Indianapolis, Indiana, 46202-5121
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224
Jefferson City Medical Group
Jefferson City, Missouri, 65203
Kinston Medical Specialists PA
Kinston, North Carolina, 28501
Innovative Clinical Research
Lafayette, Colorado, 80026
Clinical Trials of SW Louisiana LLC
Lake Charles, Louisiana, 70601
Montefiore Medical Center PRIME
Lake Success, New York, 11041
High Desert Gastroenterology, Inc.
Lancaster, California, 93534
Florida Center for Gastroenterology
Largo, Florida, 33777
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
University of Kentucky Medical Center
Lexington, Kentucky, 40536
Dcr-Pi Pc
Litchfield Park, Arizona, 85340
Gastroenterology Associates PA
Little Rock, Arkansas, 72205
University of Southern California Medical Center
Los Angeles, California, 90032
Cedars Sinai Medical Center
Los Angeles, California, 90048
University of Louisville
Louisville, Kentucky, 40202
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53705
Dean Clinic Oregon
Madison, Wisconsin, 53716
The Feinstein Institute for Medical Research PRIME
Manhasset, New York, 11030
Arizona Digestive Health
Mesa, Arizona, 85024
University of Miami
Miami, Florida, 33136
Advance Medical Research Center
Miami, Florida, 33155
Cordova Research Institute
Miami, Florida, 33155
Sanitas Research
Miami, Florida, 33155
Galiz Research LLC
Miami Springs, Florida, 33166
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Winthrop University Hospital
Mineola, New York, 11501
Facey Medical Foundation
Mission Hills, California, 91345
Clinical Trials of America, LLC
Mount Airy, North Carolina, 27030
Gastroenterology Group of Naples
Naples, Florida, 34102
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
Yale University
New Haven, Connecticut, 06520
New York University School of Medicine
New York, New York, 10016
Mount Sinai School of Medicine
New York, New York, 10029
Columbia University Medical Center
New York, New York, 10032
Digestive and Liver Disease Specialists
Norfolk, Virginia, 23502
Henry Ford Health System
Novi, Michigan, 48377
Oklahoma Foundation for Digestive Research
Oklahoma City, Oklahoma, 73104
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
GCRM
Orlando, Florida, 32801
Center For Digestive Health
Orlando, Florida, 32803
Digestive Health Center
Pasadena, Texas, 77505
Drexel University College of Medicine
Philadelphia, Pennsylvania, 19102
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, 19104
Arizona Digestive Health
Phoenix, Arizona, 85006
Phoenix Childrens Hospital
Phoenix, Arizona, 85016
Advanced Medical Research Center
Port Orange, Florida, 32127
Oregon Health & Science University
Portland, Oregon, 97229
Premier Medical Group of the Hudson Valley PC
Poughkeepsie, New York, 12601
Health Science Research Center, LLC
Pratt, Kansas, 67124
Rhode Island Hospital
Providence, Rhode Island, 02903
Hunter Holmes Mcguire Ctr
Richmond, Virginia, 23249
Mayo Clinic
Rochester, Minnesota, 55905
University of Rochester
Rochester, New York, 14642
East Coast Institute for Research LLC
Saint Augustine, Florida, 32086
University of Utah Division of Gastroenterology
Salt Lake City, Utah, 84132
Medical Associates Research Group Inc.
San Diego, California, 902123
University of California at San Francisco (PARENT)
San Francisco, California, 94115
Mayo Clinic Arizona
Scottsdale, Arizona, 85259
Virginia Mason Medical Center
Seattle, Washington, 98101
Harborview Medical Center
Seattle, Washington, 98104
Swedish Medical Center Cancer Institute Research
Seattle, Washington, 98104
University of Washington School of Medicine
Seattle, Washington, 98104
Louisiana Research Center LLC
Shreveport, Louisiana, 71103
Texas Digestive Disease Consultants - Southlake
Southlake, Texas, 76092
Mercy Research
Springfield, Missouri, 65806
Springfield Health Care Center
Springfield, Ohio, 45504
Saint Louis University
St Louis, Missouri, 63110 - 0250
Penn State University Milton S Hershey Medical Center
State College, Pennsylvania, 16803
Arizona Digestive Health
Sun City, Arizona, 85351
Atlanta Gastroenterology Specialists PC
Suwanee, Georgia, 30024
Clinical Research of West Florida, Inc.
Tampa, Florida, 33603
HCP Clinical Research LLC
Torrance, California, 90502
Charm City Research Group
Towson, Maryland, 21204
Digestive Health Specialists of Tyler
Tyler, Texas, 75701
The Vancouver Clinic
Vancouver, Washington, 98664-4896
Ventura Clinical Trials
Ventura, California, 93003
Mercy Research
Washington, Missouri, 63090
Advanced Clinical Research
West Jordan, Utah, 84088
Cleveland Clinic Florida Weston
Weston, Florida, 33331
Heartland Research Associates LLC
Wichita, Kansas, 67207
Via Christi Research a division of Via Christi Hospitals Wichita Inc
Wichita, Kansas, 67208
Trial Management Associates LLC
Wilmington, North Carolina, 28401
PMG Research of Winston-Salem
Winston-Salem, North Carolina, 27103
Shafran Gastroenterology Center
Winter Park, Florida, 32789
UMass Medical Center
Worcester, Massachusetts, 01655
Gastroenterology Associates of Western Michigan PLC
Wyoming, Michigan, 49519
Germany17 sites
Charite - Campus Virchow-Klinikum
Berlin, 13353
DRK Kliniken Berlin Westend
Berlin, 14050
St. Josef-Hospital
Bochum, 44791
Staedisches Klinikum Brandenburg
Brandenburg an der Havel, 14770
Universitaetsklinikum Carl Gustav Carus
Dresden, 01307
Universitaetsklinikum Erlangen
Erlangen, 91054
Universitaetsklinikum EssenZentrum fuer Innere Medizin
Essen, 45122
Kliniken Essen-Mitte
Essen, 45136
Katholische Kliniken Ruhrhalbinsel GmbH
Essen, 45257
Crohn Colitis Centrum Rhein Main
Frankfurt, 60594
Asklepios Klinik Hamburg
Hamburg, 22559
Universitaetsklinikum Schleswig Holstein Campus Kiel
Kiel, 24105
EUGASTRO GmbH
Leipzig, 4103
Gastroenterologische Praxis Minden
Minden, 32423
Universitatsklinikum Regensburg
Regensburg, 93042
Universitaetsklinikum Ulm
Ulm, 89081
HELIOS Klinikum Wuppertal
Wuppertal, 42283
Turkey (Türkiye)15 sites
Ankara University Medical Faculty
Ankara, 06100
Hacettepe University Medical Faculty
Ankara, 06100
Turkiye Yuksek Ihtisas Hospital
Ankara, 06100
Gazi University Medical Faculty
Ankara, 06500
Firat University Medical Faculty
Elâzığ, 23119
Istanbul University Cerrahpasa Medical Faculty
Istanbul, 34098
Acibadem Fulya Hospital
Istanbul, 34349
Haydarpasa Numune Training and Research Hospital
Istanbul, 34668
Istanbul Medeniyet Uni Goztepe Training&Res Hosp
Istanbul, 34854
Marmara University Pendik Training and Research Hospital
Istanbul, 34899
Ege University Medical Faculty
Izmir, 35100
Dokuz Eylul University Izmir
Izmir, 35340
Kocaeli Derince Training and Research Hospital
Kocaeli, 41380
Inonu Uni. Med. Fac.
Malatya, 44280
Mersin University Medical Faculty
Mersin, 33020
Australia14 sites
Royal Adelaide Hospital Institute of Medical and Veterinary Science
Adelaide, South Australia, 5000
Ballarat Base Hospital
Ballarat, 3350
Monash Medical Centre Clayton
Bentleigh East, 3165
Box Hill Hospital
Box Hill, Victoria, 3128
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050
Concord Repatriation General Hospital
Concord, New South Wales, 2139
St Vincents Hospital Melbourne
Fitzroy, 3065
Centre For Digestive Diseases
Five Dock, New South Wales, 2046
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029
Liverpool Hospital
Liverpool, New South Wales, 2170
The Alfred Hospital
Melbourne, Victoria, 3004
Fiona Stanley Hospital
Murdoch, Western Australia, 6150
Mater Adult Hospital
South Brisbane, Queensland, 4101
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102
Italy12 sites
Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi
Bologna, 40138
Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico
Milan, 20122
Azienda Ospedaliera Di Padova
Padova, 35128
Azienda Ospedaliera Vincenzo Cervello
Palermo, 90146
Fondazione IRCCS Policlinico San Matteo
Pavia, 27100
Azienda Ospedaliero Universitaria Pisana
Pisa, 56124
Universita Campus Bio-Medico di Roma
Roma, 00128
Complesso Integrato Columbus
Roma, 00168
Azienda Ospedaliera San Camillo Forlanini
Rome, 00152
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Rome, 133
Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi dAragona
Salerno, 84131
IRCCS Policlinico San Donato
San Donato Milanese, 20097
France11 sites
CHU Amiens Hopital Sud
Amiens, 80054
CHU Besancon Hopital Jean Minjoz
Besançon, 25030
Hopital Claude Huriez CHRU Lille
Lille, 59037
Hopital Nord CHU Marseille
Marseille, 13915
CHU Nice Hopital de lArchet 2
Nice, 06200
Hopital Saint Louis
Paris, 75475
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495
CHU Reims Hopital Robert Debre
Reims, 51092
CHU de Rouen Hopital Charles Nicolle
Rouen, 76031
CHU de Toulouse Hopital Rangueil
Toulouse, 31059
Hopital de Brabois Adultes
Vandœuvre-lès-Nancy, 54511
South Korea11 sites
Dong-A University Hospital
Busan, 49201
Pusan National University Hospital
Busan, 49241
Hanyang Univerisy Guri Hospital
Guri-si, 471-701
CHA Bundang Medical Center CHA University
Seongnam-si, 13496
Seoul National University Bundang Hospital
Seongnam-si, 13620
Kyung Hee University Hospital
Seoul, 02447
Ewha Womans University Mokdong Hospital
Seoul, 158-710
Seoul National University Hospital
Seoul, 3080
Kangbuk Samsung Hospital
Seoul, 3181
The Catholic University of Korea, St. Vincent's Hospital
Suwon, 16247
Yonsei University Wonju Severance Christian Hospital
Wŏnju, 220701
Spain9 sites
Hospital General Universitario de Alicante
Alicante, 03010
Hospital del Mar
Barcelona, 08003
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041
Hospital Universitario de la Princessa
Madrid, 28006
Hospital General Universitario Gregorio Maranon
Madrid, 28007
Hospital Universitario Ramon y Cajal
Madrid, 28034
Hospital Universitario La Paz
Madrid, 28046
Complejo Hospitalario de Pontevedra
Pontevedra, 36164
Hospital Universitario Miguel Servet
Zaragoza, 50009
Ukraine9 sites
CI of PH Kharkiv CCH #2
Kharkiv, 61037
Treatment-Diagnostic Center of Private Enterprise of PMF Atsynus
Kirovohrad, 25006
Kyiv City Clinical Hospital #1
Kyiv, 02091
CI Odesa Regional Clinical Hospital
Odesa, 65025
CI of SRC Sumy RCH Dept of Rheumatology Sumy SU MI
Sumy, 40022
Ternopil City Communal Emergency Medical Care Hospital
Ternopil, 46000
SRI of Invalid Rehabilitation EST Complex of Vinnytsia M.I.Pyrogov NMU MOHU
Vinnytsia, 21029
SI Branch CH of Zaporizhzhia Station-2 of SE Prydniprovska Railway Dept of Surgery Zaporizhzhia SMU
Zaporizhia, 69104
CI Zaporizhzhia Regional Clinical Hospital of ZRC
Zaporizhzhya, 69600
United Kingdom9 sites
Basingstoke and North Hampshire Hospital
Basingstoke, RG24 9NA
University Hospital Coventry
Coventry, CV2 2DX
Queen Elizabeth University Hospital
Glasgow, G51 4TF
Hull Royal Infirmary
Hull, HU3 2JZ
Royal London Hospital
London, E1 1BB
University College London Hospitals
London, NW1 2PG
Manchester Royal Infirmary
Manchester, M13 9WL
Nottingham University Hospitals Queens Medical Centre
Nottingham, NG7 2UH
Borders General Hospital
Roxburghshire, TD6 9BS
Canada8 sites
Barrie GI Associates
Barrie, Ontario, L4M 7G1
Alberta Childrens Hospital
Calgary, Alberta, T3B 6A8
Centre de sante et de services sociaux Champlain Charles Le Moyne
Greenfield Park, Quebec, J4V 2H1
LHSC - Victoria Hospital
London, Ontario, N6A 5W9
Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8
Mount Sinai Hospital
Toronto, Ontario, M5G 1X5
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8
GI Research Institute
Vancouver, British Columbia, V6Z 2K5
Denmark6 sites
Aarhus Universitetshospital
Aahus C, 8000
Alborg Universitets Hospital
Aalborg, 9000
Hvidovre Hospital
Hvidovre, 2650
Koge Sygehus
Køge, 4600
Odense Universitetshospital
Odense C, 5000
Regionshospitalet Silkeborg
Silkeborg, 8600
Poland6 sites
SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego
Bialystok, 15-275
Clinsante S.C. Osrodek Badan Klinicznych
Bydgoszcz, 85-794
Centrum Medyczne A-Z Clinic
Krakow, 31-315
Centrum Medyczne AMED
Lodz, 91-365
Nzoz Vivamed
Warsaw, 03-580
LexMedica Osrodek Badan Klinicznych
Wroclaw, 53-114
Belgium5 sites
Hopital Universitaire des Enfants
Brussels, 1020
Cliniques Universitaires Saint-Luc
Brussels, 1200
UZ Antwerpen
Edegem, 2650
Universitair Ziekenhuis Gent
Ghent, 9000
CHU Sart Tilman
Liège, 4000
Portugal5 sites
Hospital de Braga
Braga, 4710-243
Hospital da Senhora da Oliveira Guimaraes
Guimarães, 4835-044
Hospital Da Luz
Lisbon, 1500-650
Centro Hospitalar de Sao Joao, EPE
Porto, 4200-319
Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE
Viana do Castelo, 4904-858
Russia5 sites
Medical Center Stolitsa-Medikl
Moscow, 115088
SBEIHPE Novosibirsk State Medical University
Novosibirsk, 630084
FSBI Scientific Research Institute of Physyology and Basic Medicine under the SB of RAMS
Novosibirsk, 630117
SPb SBIH City Hospital # 26
Saint Petersburg, 196247
NonState Healthcare Institution Central Clinical Hospital, Samara station JSC Russian Railways
Samara, 443041
Czechia4 sites
Hepato-Gastroenterologie HK, s. r. o.
Hradec Králové, 500 12
PreventaMed
Olomouc, 77900
CCBR Prague CZ
Prague, 13000
Thomayerova nemocnice
Prague, 14059
Hungary4 sites
Obudai Egeszsegugyi Centrum Kft.
Budapest, 1036
Semmelweis Egyetem
Budapest, 1088
Szent Margit Korhaz
Budapest, H-1032
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szent-Gyorgyi Albert TE AOK Borgyogy
Szeged, 6720
Switzerland4 sites
Inselspital - Universitaetsspital Bern
Bern, 3010
Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner
Bern, 3012
Hopitaux Universitaires de Geneve-HUG
Geneva, 1205
UniversitatSspital Zurich
Zurich, 8091
Austria3 sites
Klinikum Klagenfurt am Wörtersee
Klagenfurt, 9020
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, 5020
Krankenanstalt Rudolfstiftung Wien
Wein, 1030
Greece3 sites
General Hospital of Athens Evangelismos
Athens, 10676
Athens Medical Center
Athens, 15125
University General Hospital of Patras
Rio Patras, 26500
Israel3 sites
Rabin Medical Center
Petah Tikva, 49100
Kaplan Medical Center
Rehovot, 76100
Assaf Harofeh Medical Center
Tsrifin, 70300
Finland2 sites
Helsingin yliopistollinen keskussairaala
Helsinki, FI-00290
Tampereen yliopistollinen sairaala
Tampere, 33521
Latvia2 sites
Digestive Diseases Center Gastro
Riga, LV-1006
Riga East Clinical University Hospital clinic Gailezers
Riga, LV-1038
Netherlands2 sites
Amphia Ziekenhuis
Breda, 4819 EV
Erasmus Medisch Centrum
Rotterdam, 3015 CE
Romania2 sites
CMI Dr. Tirnaveanu Amelita
Oradea, 410066
Centrul de Gastroenterologie Dr. Goldis
Timișoara, 300002
About this study
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
The purpose of study is to test the effect of an experimental medication GED-0301(mongersen) and evaluate its safety in patients (≥ 12 years of age) with active Crohn's disease. The study will test GED-0301 compare to placebo for 12 weeks. The study treatment is blinded which means that patients and the study doctor will not know which treatment has been assigned. Patients in this study will be allowed treatment with stable doses of oral aminosalicylates, oral corticosteroids, immunosupressants and antibiotics for the treatment of Crohn's disease. Adolescent patients will also be allowed treatment with stable doses of exclusive enteral nutrition and growth hormone.
All patients who complete the study will have the option to enter a long term active treatment study.
- Conditions
- Crohn Disease
- Being tested
- GED-0301, Placebo
- Keywords
- Crohn's Disease, GED-0301, Mongersen, Adolescent, Pediatric, Children
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GED-0301Drug
Also called Mongersen
GED-0301
PlaceboDrug
Placebo
| Study group | Role | What they receive |
|---|---|---|
| GED-0301 1 x 160 mg once daily | Experimental | GED-0301 1 x 160 mg tablet once daily (QD) Receives: Drug: GED-0301 |
| GED-0301 - 4 x 40 mg once daily | Experimental | GED-0301 4 x 40 mg tablets once daily (QD) Receives: Drug: GED-0301 |
| Placebo once daily | Placebo comparator | Placebo once daily (QD) Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical remission defined by an average daily liquid or soft stool frequency and abdominal pain score (US) and Crohn's Disease Activity Index (CDAI) (Rest of World)
The proportion of subjects achieving clinical remission at Week 12.
Measured: week 12
Secondary outcomes (6)
Clinical remission defined by an average daily liquid or soft stool frequency and abdominal pain score (US) and CDAI
The proportion of subjects achieving clinical remission at Week 4, Week 12.
Measured: Week 4, week 12
Endoscopic improvement by the Simple Endoscopic Score for Crohn's Disease (SES-CD)
Endoscopic improvement of the mucosa at Week 12.
Measured: Week 12
Clinical response defined by CDAI
The proportion of subjects achieving clinical response at Week 4, Week 12.
Measured: Week 4, week 12
Clinical remission defined by PCDAI
The proportion of subjects achieving clinical remission at Week 12 (adolescent subjects only).
Measured: Week 12
Adverse Events (AEs)
Incidence and severity of adverse events
Measured: Up to 20 weeks
Pharmacokinetics (PK)- plasma concentration of GED-0301
The plasma concentration of GED-0301 at Week 4, Week 8
Measured: Week 4, week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2016 (estimated)
- Study start1 Dec 2017 (estimated)
- Primary completion17 Nov 2018 (estimated)
- Study completion24 Dec 2018 (estimated)
Why it stopped: Sponsor decision not to start trial
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn DiseaseStudies of the same condition, open and under way.
- More trials run by CelgeneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Celgene
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Denesh Chitkara, MD, Study director, Celgene Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02974322
- Sponsor's protocol ID
- GED-0301-CD-003
- Status last verified
- Nov 2017
- First submitted
- 23 Nov 2016
- Last updated
- 14 Nov 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
- ClinicalTrials.gov ID
- NCT02974322
- Acronym / sponsor ID
- GED-0301-CD-003
- Conditions
- Crohn Disease
- Keywords
- Crohn's Disease, GED-0301, Mongersen, Adolescent, Pediatric, Children
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Sponsor decision not to start trial
- Enrolment
- 0 participants (actual)
- Lead sponsor
- CelgeneIndustry (pharma, biotech, devices)
- Study start
- 1 Dec 2017 (estimated)
- Primary completion
- 17 Nov 2018 (estimated)
- Study completion
- 24 Dec 2018 (estimated)
- First posted
- 28 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of study is to test the effect of an experimental medication GED-0301(mongersen) and evaluate its safety in patients (≥ 12 years of age) with active Crohn's disease. The study will test GED-0301 compare to placebo for 12 weeks. The study treatment is blinded which means that patients and the study doctor will not know which treatment has been assigned. Patients in this study will be allowed treatment with stable doses of oral aminosalicylates, oral corticosteroids, immunosupressants and antibiotics for the treatment of Crohn's disease. Adolescent patients will also be allowed treatment with stable doses of exclusive enteral nutrition and growth hormone.
All patients who complete the study will have the option to enter a long term active treatment study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| GED-0301 1 x 160 mg once daily | Experimental | Drug: GED-0301GED-0301 1 x 160 mg tablet once daily (QD) |
| GED-0301 - 4 x 40 mg once daily | Experimental | Drug: GED-0301GED-0301 4 x 40 mg tablets once daily (QD) |
| Placebo once daily | Placebo comparator | Drug: PlaceboPlacebo once daily (QD) |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Male or female ≥ 12 years
- Subject is able to swallow the IP tablets
- Active Crohn's disease (CD) disease as determined by the Crohn's Disease Activity Index (CDAI) score and the Simple Endoscopic Score for Crohn's Disease (SES-CD)
- Must meet a determined average minimum number of daily stools or rating of abdominal pain over a 7day period
- Subject must have failed or experienced intolerance to at least one of the following: budesonide; systemic corticosteroids; immunosuppressants (eg, azathiopurine, 6-mercaptopurine, or methotrexate); or biologics for the treatment of CD (ie, infliximab, adalimumab, certolizumab, or vedolizumab).
Key exclusion criteria (7 listed)
- The presence of any of the following will exclude a subject from enrollment: Diagnosis of ulcerative colitis (UC), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis, or colitis due to immunodeficiency
- Local manifestations of Crohn's Disease (CD) such as abscesses, short bowel syndrome; or other disease complications for which surgery might be indicated or could confound the evaluation of efficacy
- Subject has strictures with prestenotic dilatation, requiring procedural intervention, or with obstructive symptoms. In addition, subjects with colonic strictures that are not passable with an age-appropriate colonoscope, or strictures in the ileum or ileocecal valve that are fibrotic in nature, will be excluded
- Intestinal resection within 6 months or any intra-abdominal surgery within 3 months prior to the Screening Visit
- Ileostomy or a colostomy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GED-0301Also: MongersenGED-0301 | Drug | GED-0301 - 4 x 40 mg once daily, GED-0301 1 x 160 mg once daily |
| PlaceboPlacebo | Drug | Placebo once daily |
Primary outcome
Clinical remission defined by an average daily liquid or soft stool frequency and abdominal pain score (US) and Crohn's Disease Activity Index (CDAI) (Rest of World)
Time frame: week 12
The proportion of subjects achieving clinical remission at Week 12.
6 secondary outcomes
Clinical remission defined by an average daily liquid or soft stool frequency and abdominal pain score (US) and CDAI
Time frame: Week 4, week 12
Endoscopic improvement by the Simple Endoscopic Score for Crohn's Disease (SES-CD)
Time frame: Week 12
Clinical response defined by CDAI
Time frame: Week 4, week 12
Clinical remission defined by PCDAI
Time frame: Week 12
Adverse Events (AEs)
Time frame: Up to 20 weeks
Pharmacokinetics (PK)- plasma concentration of GED-0301
Time frame: Week 4, week 8
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2017.
Related trials for Crohn Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Denesh Chitkara, MD study director
Celgene Corporation
311 sites in 30 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing GED-0301 in people with Crohn Disease, run by Celgene at 311 sites in 30 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 14 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 311 sites in United States, Germany, Turkey (Türkiye), Australia, Italy and 25 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical remission defined by an average daily liquid or soft stool frequency and abdominal pain score (US) and Crohn's Disease Activity Index (CDAI) (Rest of World) (time frame: week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2017.